The role of hypoxia and acidosis in promoting metastasis and resistance to chemotherapy

被引:85
作者
DeClerck, Katie [1 ]
Elble, Randolph C. [2 ,3 ]
机构
[1] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL 62794 USA
[2] So Illinois Univ, Sch Med, Dept Pharmacol, Springfield, IL 62794 USA
[3] So Illinois Univ, Sch Med, SimmonsCooper Canc Inst, Springfield, IL 62794 USA
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2010年 / 15卷
关键词
hypoxia; HIF; Acidosis; Microenvironment; TAM; Macrophages; Bioreductive; Review; TUMOR-ASSOCIATED MACROPHAGES; INDUCIBLE FACTOR 1-ALPHA; ENDOTHELIAL GROWTH-FACTOR; SQUAMOUS-CELL CARCINOMA; INDUCED GENE-EXPRESSION; BREAST-CARCINOMA; IN-VIVO; FACTOR-2-ALPHA HIF-2-ALPHA; ANTICANCER THERAPIES; PROSTATE-CANCER;
D O I
10.2741/3616
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
By a multiplicity of mechanisms, hypoxia and acidosis create a nurturing environment for tumor progression and the evolution of metastatic, drug-resistant cells. Acidosis drives mutagenesis and promotes the subversion of checkpoints and apoptotic mechanisms. Hypoxic tissues secrete cytokines that undermine normal anti-tumor surveillance by macrophages, turning them into accomplices and facilitators of invasion and angiogenesis. Invasiveness is also abetted by acidosis, the result of shifting to an anaerobic glycolytic metabolism. These factors explain the generally poor prognosis indicated by tumors expressing hypoxia-inducible factor-1 (HIF-1). However, these insights into the physiology of hypoxic tumors have inspired the development of new chemotherapeutic approaches directed at these tissues, including bioreductive drugs and gene therapies, some of which are in clinical trials. The ability to target the hypoxic compartment should allow longer progression-free survival and overall survival of patients bearing solid tumor malignancies.
引用
收藏
页码:213 / 225
页数:13
相关论文
共 116 条
[1]  
Aebersold DM, 2001, CANCER RES, V61, P2911
[2]   Bacteriolytic therapy can generate a potent immune response against experimental tumors [J].
Agrawal, N ;
Bettegowda, C ;
Cheong, I ;
Geschwind, JF ;
Drake, CG ;
Hipkiss, EL ;
Tatsumi, M ;
Dang, LH ;
Diaz, LA ;
Pomper, M ;
Abusedera, M ;
Wahl, RL ;
Kinzler, KW ;
Zhou, SB ;
Huso, DL ;
Vogelstein, B .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (42) :15172-15177
[3]  
Balkwill Frances R., 1992, Progress in Growth Factor Research, V4, P121, DOI 10.1016/0955-2235(92)90027-F
[4]   Inflammation-associated immune suppression in cancer: The roles played by cytokines, chemokines and additional mediators [J].
Ben-Baruch, A .
SEMINARS IN CANCER BIOLOGY, 2006, 16 (01) :38-52
[5]   Cyclin G2 associates with protein phosphatase 2A catalytic and regulatory B′ subunits in active complexes and induces nuclear aberrations and a G1/S phase cell cycle arrest [J].
Bennin, DA ;
Don, ASA ;
Brake, T ;
McKenzie, JL ;
Rosenbaum, H ;
Ortiz, L ;
DePaoli-Roach, AA ;
Horne, MC .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (30) :27449-27467
[6]   Regulation of DNA repair in hypoxic cancer cells [J].
Bindra, Ranjit S. ;
Crosby, Meredith E. ;
Glazer, Peter M. .
CANCER AND METASTASIS REVIEWS, 2007, 26 (02) :249-260
[7]   Genetic instability and the tumor microenvironment: towards the concept of microenvironment-induced mutagenesis [J].
Bindra, RS ;
Glazer, PM .
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 2005, 569 (1-2) :75-85
[8]   The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies [J].
Bingle, L ;
Brown, NJ ;
Lewis, CE .
JOURNAL OF PATHOLOGY, 2002, 196 (03) :254-265
[9]  
Birner P, 2001, CLIN CANCER RES, V7, P1661
[10]   p53 inhibits hypoxia-inducible factor-stimulated transcription [J].
Blagosklonny, MV ;
An, WG ;
Romanova, LY ;
Trepel, J ;
Fojo, T ;
Neckers, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (20) :11995-11998